We propose a clinical trials unit (CTU) with a single integrated research site (CRS) at GHESKIO in Port-au-Prince, Haiti. GHESKIO is the acronym for Groupe Haitian d'Etude du Sarcoma da Kaposi at des Infections Opportunistas. The CTU/CRS will focus on the rapid implementation of clinical research sponsored by three of the NIAID Networks - Adult HIV Therapeutic strategies (ACTG), HIV vaccines (HVTN), and the International Maternal-Pediatric-Adolescent AIDS Clinical Trials Network (IMPAACT). The CTU will also contribute new ideas for Network clinical trials. GHESKIO has consistently been ranked among the top several sites in recruitment to both the ACTG and HVTN Networks, and is also a leader in maternal-child-adolescent study enrollment. The GHESKIO tripartite mission of research, patient care and training provides the patient populations, cohorts, and experienced research teams to conduct intensive Phase I to Phase IV studies. GHESKIO provides free health care to over 100,000 persons/year. In 2012 GHESKIO tested over 40,000 parsons for HIV, with 9.6% seroprevalence. Sixty percent of the new HIV infections diagnosed at GHESKIO in 2012 were women, including 485 pregnant women. Haiti has the highest prevalence of HIV infection in this hemisphere with an incidence of 2.0% in high-risk heterosexual populations and a clade B strain. GHESKIO currently has over 15,000 patients receiving ART and follows several thousand children and adolescents. Tuberculosis research capitalizes on GHESKIO's unique resources - a BSL-3 laboratory, a 30-bed MDR-TB research hospital under construction, and a local TB incidence of 768 cases/100,000 persons. GHESKIO diagnosed and treated 1,666 new TB cases in 2012. The capacity of GHESKIO to rapidly adapt was demonstrated by its response to the 2010 earthquake and the subsequent cholera epidemic. In 2012, GHESKIO also successfully immunized 50,000 high-risk persons for cholera in the slums adjacent to its clinics. This record of productivity and the breadth of GHESKIO's clinical, laboratory, and staff resources assure significant contributions will continue to be made in the Networks.
The GHESKIO CTU/CRS will conduct research in the areas of adult HIV therapeutic strategies (ACTG), HIV vaccines (HVTN), and on HIV infection in pediatric and maternal populations (IMPAACT). The goal is to increase our ability to prevent and to treat HIV/AIDS and its associated conditions.
|Bristow, Claire C; Lee, Sung-Jae; Severe, Linda et al. (2017) Attributes of diagnostic tests to increase uptake of dual testing for syphilis and HIV in Port-au-Prince, Haiti. Int J STD AIDS 28:259-264|
|Masur, Jack; Koenig, Serena P; Julma, Pierrot et al. (2017) Active Tuberculosis Case Finding in Haiti. Am J Trop Med Hyg 97:433-435|
|Koenig, Serena P; Dorvil, Nancy; Dévieux, Jessy G et al. (2017) Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med 14:e1002357|
|Wolff, Marcelo J; Giganti, Mark J; Cortes, Claudia P et al. (2017) A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy. PLoS One 12:e0179769|
|Batavia, Ashita S; Secours, Rode; Espinosa, Patrice et al. (2016) Diagnosis of HIV-Associated Oral Lesions in Relation to Early versus Delayed Antiretroviral Therapy: Results from the CIPRA HT001 Trial. PLoS One 11:e0150656|
|Sévère, Karine; Rouzier, Vanessa; Anglade, Stravinsky Benedict et al. (2016) Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up. Am J Trop Med Hyg 94:1136-42|
|Sévère, Karine; Rouzier, Vanessa; Anglade, Stravinsky Benedict et al. (2016) In Response. Am J Trop Med Hyg 95:495-6|
|Deschamps, Marie M; Metch, Barbara; Morgan, Cecilia A et al. (2016) Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907. J Acquir Immune Defic Syndr 71:70-7|
|Ocheretina, Oksana; Byrt, Erin; Mabou, Marie-Marcelle et al. (2016) False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load. Diagn Microbiol Infect Dis 85:53-5|
|Bristow, Claire C; Severe, Linda; Pape, Jean William et al. (2016) Dual rapid lateral flow immunoassay fingerstick wholeblood testing for syphilis and HIV infections is acceptable and accurate, Port-au-Prince, Haiti. BMC Infect Dis 16:302|
Showing the most recent 10 out of 55 publications